Viewing Study NCT01712295


Ignite Creation Date: 2025-12-24 @ 1:59 PM
Ignite Modification Date: 2025-12-28 @ 1:05 PM
Study NCT ID: NCT01712295
Status: UNKNOWN
Last Update Posted: 2012-10-23
First Post: 2012-10-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts
Sponsor: Grossman, Michael, D.P.M.
Organization:

Study Overview

Official Title: New Formulation of Salicylate to Improve Treatment of Common Skin Warts
Status: UNKNOWN
Status Verified Date: 2012-10
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Plantar warts on the sole of the foot are among the most common warts seen in podiatry clinics. Some patients are readily cured by simple standard of care treatments that include wart debridement (trimming or excision) and application of 17% salicylate (commercially known as Compound W)or by other treatments that may be painful and affect mobility. No treatment is consistently effective and most patients fail treatment multiple times.

Ethyl pyruvate (EP)is a common food additive noted to be 'generally regarded as safe' that may improve the activity of salicylate in wart treatment by improving the ability to penetrate and/or persist in the skin. The use of 17% salicylate with the addition of EP may improve cures of common foot plantar warts in subjects who also be receiving other standard-of-care treatment.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: